Rafael Holdings, Inc. RFL Healthcare One — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rafael Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Rafael Holdings, Inc.’s 10-Q, filed June 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rafael Holdings, Inc.'s healthcare one — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rafael Holdings, Inc.'s healthcare one — research and development expense?
- Rafael Holdings, Inc. (RFL) reported healthcare one — research and development expense of $4.85M in Q1 2026.
- How has Rafael Holdings, Inc.'s healthcare one — research and development expense changed year-over-year?
- Rafael Holdings, Inc.'s healthcare one — research and development expense increased by 61.6% year-over-year, from $3M to $4.85M.
- What does healthcare one — research and development expense mean?
- Captures the costs associated with the discovery, clinical testing, and development of new pharmaceutical therapies within the Healthcare One segment. High levels of this expense reflect the company's commitment to advancing its oncology pipeline toward commercialization.